RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $105 to $100.